Introduction {#s1}
============

Neural tube closure defects (NTDs) are common congenital malformations in humans, affecting approximately 1 in 1000 births. During embryogenesis, the neural plate undergoes shaping, before neural folds develop and elevate, contact, and then fuse at the midline to create the closed tube structure that will form the spinal cord and brain ([@bib14]). Studies in *Xenopus*, zebrafish, and subsequently mouse, revealed a role for planar cell polarity (PCP) signaling in this process. Further, it was demonstrated that *Looptail* (*Lp*) mice, with mutations in the *mVangl2* locus (see below), fail to establish a neural plate width that will allow for bending and closure ([@bib24]; [@bib64]; [@bib65]; [@bib71]). Consistent with a role in neurulation, *Vangl2* (an orthologue of the *Drosophila* PCP core gene *Van Gogh/Vang*) is expressed broadly in the neural plate prior to, during, and after closure ([@bib38]). Interestingly, the second orthologous mouse gene, *Vangl1*, is also expressed in this tissue; however, its expression is more restricted, showing a complementary pattern with *Vangl2* ([@bib22]; [@bib62]; [@bib61]).

*Lp* was originally defined by two independent mutations (D255E and S464N) in *mVangl2* that map to the C-terminal tail. Both display an identical phenotype, with homozygous mice developing craniorachischisis, a completely open neural tube ([@bib38]; [@bib47]). At the molecular level, the mutations were found to disrupt binding between Vangl2 and effectors and also showed reduced membrane localization, decreased protein levels, and defective phosphorylation of Vangl2 ([@bib20]; [@bib27]; [@bib30]; [@bib49]; [@bib55]; [@bib60]; [@bib61]). Overall, this led to suggestions that the mutants are loss-of-function (LOF), and that Vangl2 is a rate-limiting component in a dosage-sensitive pathway. However, this is in contrast to the earliest genetic studies, which suggested a semi-dominant mutation with incomplete penetrance. This was due to the presence of a looped tail phenotype in the majority of, but not all heterozygotes, caused by delay of posterior neuropore closure ([@bib13]; [@bib56]). Since the original identification of the *Vangl2^Lp^* alleles, other PCP mutant mice were found to develop NTDs, implicating the pathway defects as a disease risk factor ([@bib4]; [@bib16]; [@bib24]; [@bib31]; [@bib44]; [@bib48]; [@bib65]; [@bib66]). Due to this strong correlation, efforts began to investigate whether human NTD patients might also exhibit mutations in PCP components.

A number of mutations were identified in patient populations in *VANGL1* and *VANGL2*, as well as additional core PCP and associated proteins (reviewed in [@bib36]). In each case, the mutation was heterozygous and, interestingly, familial mutations could be found to result in different disease severity among family members. However, this is perhaps not surprising given the complex etiology of NTDs, which are thought to result from a mixture of genetic and environmental factors. Furthermore, digenic mutations were also discovered among PCP genes, consistent with a multifactorial hypothesis, whereby additional factors would be required to achieve a threshold for disease progression ([@bib3]; [@bib6]; [@bib12]; [@bib19]; [@bib43]; [@bib67]). This is additionally supported by chimeric mouse studies using the *Lp* allele that showed an all-or-nothing effect in developing craniorachischisis ([@bib50]).

Despite the progress in identifying mutations within PCP components, data is lacking as to whether these mutations are in fact pathological, with only a few studies addressing this question to date ([@bib34]; [@bib39]; [@bib42]; [@bib51]). Furthermore, evidence has emerged that the *mVangl2^Lp^* allele may in fact be a dominant negative mutation ([@bib55]; [@bib72]), indicating there is more to investigate surrounding its molecular behavior. In addition, a recessive *mVangl2^Lp^* mutation was discovered (with substitution R259L) that gave an apparently normal phenotype in heterozygotes. In this case, only 47% of homozygote animals displayed a looped tail and 12% developed spina bifida, a milder NTD as compared to craniorachischisis, leading to the suggestion that this *Lp* mutation is a hypomorphic *Vangl2* LOF allele ([@bib30]; [@bib66]; [@bib72]).

Polarization of epithelial cells, and cells in general, is critical for the morphogenesis and function of mature tissues, with perturbation of cellular polarity and tissue organization implicated in numerous diseases. Epithelial cell polarity can be derived in two axes, apical-basal and orthogonal to the plane of the epithelium, which is referred to as planar cell polarity (PCP). PCP establishment is governed by members of the conserved non-canonical Wnt/Frizzled-PCP pathway. Besides the four-pass trans-membrane protein Vang (Vangl1 and Vangl2 in mammals, see above), which was - like all other core PCP factors - originally discovered in *Drosophila* ([@bib59]), a.k.a. *strabismus/stbm* ([@bib69]), they include the atypical cadherin Flamingo (Fmi; Celsr in mammals), the seven-pass transmembrane protein Frizzled (Fz; Fzd in vertebrates with several family members), and the cytoplasmic proteins Dishevelled (Dsh; Dvl in mammals), Diego (Dgo; Inversin/Diversin in vertebrates), and Prickle (Pk). The pathway is synonymous with the asymmetric localization of these core members, which form into two sub-complexes on opposite sides of a given cell, creating an intracellular bridge to convey polarity across the tissue. The complexes also direct spatially restricted downstream signaling through tissue-specific effectors, leading to cytoskeletal rearrangement in the majority of cases ([@bib2]; [@bib28]; [@bib32]; [@bib54]; [@bib63]; [@bib70]).

Asymmetric localization of PCP complexes is directly observable in cells of the *Drosophila* wing where they align to the proximal-distal axis. Molecular interactions promote the formation of stable complexes at proximal (Fmi-Vang-Pk) and distal (Fmi-Fz-Dsh-Dgo) cell membranes, with Fmi forming a homotypic interaction across cells. In the wing, signaling leads to the formation of a single-actin rich hair at the distal vertex of each cell. While in other tissues displaying visible PCP features, phenotypes can include fate specification or coordinated cell movement ([@bib2]; [@bib28]; [@bib32]; [@bib54]). For example, in the *Drosophila* eye, PCP signaling is responsible for determining the differential fate specification of photoreceptors R3 and R4, which also directs rotation and subsequent orientation of the photoreceptor clusters, referred to as ommatidia. These signaling events in turn lead to a mirror-image arrangement of ommatidia across the dorso-ventral midline, or equator. Disruption of PCP in the wing leads to misorientation of cellular hairs or multiple wing hairs ([@bib2]; [@bib28]; [@bib32]; [@bib54]), while in the eye chirality or rotation defects of the ommatidia are observed ([@bib45]; [@bib58]).

The importance of PCP during vertebrate development and disease has also become widely recognized ([@bib28]; [@bib32]; [@bib53]; [@bib68]). The PCP pathway is highly conserved in vertebrates, with different tissues displaying PCP readouts or defects upon misregulation ([@bib28]; [@bib68]; [@bib70]). One example of this is the above mentioned *mVangl2^Lp^*, and the first example of a link between PCP signaling and NTDs ([@bib38]; [@bib47]). Based on the fact that several human patient-derived *VANGL1*/2 mutations exist, and the availability of comparable mouse alleles, we set out to investigate how these alleles impact PCP signaling functionally in a uniform defined genetic background. For this we utilized *Drosophila*. Overall, we focused on six mutations located in the C-terminal tail of Vang, where all molecular interactions have been thus far mapped. We observed that all resulted in aberrant PCP signaling and phenotypes, however, to varying degrees. In the majority of cases, the mutation was dominant, either hypermorphic gain-of-function or dominant negative, leading to altered protein localization of both alleles in vivo. We were also able to show that one mutation was indeed hypomorphic in its behavior. Taken together, our analyses demonstrate in molecular detail the nature of the different *VANGL1/2* alleles. These alleles display defective PCP signaling in vivo, indicating their causative association with the NTD phenotypes of the human patient mutations.

Results {#s2}
=======

Mutations associated with mammalian NTD can be found throughout the C-terminal tail of *Vangl* genes {#s2-1}
----------------------------------------------------------------------------------------------------

The mammalian core PCP genes *Vangl1/2*, and *Vang* in *Drosophila*, play essential roles in planar polarity signaling. *Vang* interacts genetically with each PCP core gene. It has further been demonstrated that it also can physically interact with all other members of the PCP complex, and the interaction sites with the cytoplasmic PCP core factors have been mapped to its C-terminal domain ([@bib5]; [@bib17]; [@bib18]; [@bib32]; [@bib35]).

While mutations have been observed along the entire span of the *VANGL1/2* genes in human NTD patients, mutations known to be causative for NTD in the mouse all map to the C-terminal tail ([@bib10]; [@bib23]; [@bib30]; [@bib38]; [@bib47]). We were interested to explore whether the different mutations observed in human patients could impact PCP phenotypically. Furthermore, we set out to investigate how mutations found in both the mouse and human patients affected signaling at a molecular and functional level. For this, we turned to *Drosophila* as it allows for intricate and quantitative analyses, and is a genetically simpler system with less redundancy - there is only one *Vang* gene in flies - that, importantly, shows functional and mechanistic conservation ([@bib1]; [@bib2]; [@bib28]; [@bib54]). We chose to focus our attention on mutations within the C-terminal tail due to the functional importance of this region.

A number of C-terminal mutations have been discovered to date in both mice and humans and are detailed in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}. For our study, we selected two mutations from the mouse and four mutations from human patients for further analysis, these include D255E and R259L identified in mouse *Vangl2* ([@bib30]; [@bib38]), M328T and R517H found in human *VANGL1* ([@bib39]; [@bib43]), and R270H and R353C from human *VANGL2* ([@bib41]; [@bib42]; [Figure 1](#fig1){ref-type="fig"}). These mutations were selected for varying reasons. Firstly, we were interested to compare mouse D255E and R259L in a genetically uniform background, as the mutations are only a few residues apart, and strikingly the more conservative mutation (D255E) displays a more severe phenotype as compared to R259L in mouse models ([@bib30]; [@bib38]). Secondly, R270H was selected, as the residue is absolutely conserved across all species, and it covers two independent mutational events, as a mutation in *VANGL1* was also observed at the equivalent residue (see [Figure 1B](#fig1){ref-type="fig"}) in a digenic combination along with a *CELSR1* mutation ([@bib11]; [@bib39]). Thirdly, M328T was chosen because information to date suggests this mutation may be a LOF allele ([@bib51]), and R353C as it was suggested that effector binding may be reduced ([@bib42]; [Figure 1B](#fig1){ref-type="fig"}). Finally, we selected R517H, a highly conserved residue with a conservative mutation where the bioinformatic prediction of its tolerance was unclear ([Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). Overall, we analyzed mutations from both *VANGL1* and *−2*, investigated mutations spread along the length of the C-terminal tail ([Figure 1A](#fig1){ref-type="fig"}), compared conservative as well as drastic substitutions, and focused on well conserved sites across species.

![Description of Vang mutations.\
(**A**) Schematic showing the location of investigated mutations along the C-terminal tail of Vang. Mutations highlighted in yellow were originally identified in the mouse, mutations highlighted in orange were found in human NTD patients (see supplement for references). (**B**) Table displaying information concerning the selected mutations from mouse (top) and human patients (below). Details include: original mammalian mutation, nature of the mutational change (e.g. D to E is listed as conservative as both are acidic residues), equivalent residue in *Drosophila* Vang, whether the mutated residue is conserved among species, and whether the respective mutated Vangl protein was able to retain binding to the effector protein Dishevelled (Dvl).\
Figure 1---source data 1.Summary of NTD-associated mammalian mutations found to date within the C-terminal tail of *Vangl/VANGL* genes.](elife-53532-fig1){#fig1}

*Drosophila* provides a sensitive system for investigating the effect of mutations on PCP {#s2-2}
-----------------------------------------------------------------------------------------

To compare mutations in vivo in *Drosophila*, we took advantage of the Gal4/UAS system to allow for regulated expression of our transgenes ([@bib9]). We also included a Flagx3-tag and an attB (bacterial attachment) site. To enable site-specific recombination, constructs were then introduced into a fly strain containing an attP (phage attachment) docking site, along with PhiC31 integrase activity to mediate integration between the attB and P sites ([@bib8]; [@bib7]). Thus, by using the same attP docking site, we ensured insertion of the transgenes at a constant genetic locus and thus equivalent expression for accurate comparison. We chose to introduce mutations into the *Drosophila Vang* gene, rather than use mouse *Vangl2* or human *VANGL1/2*, to preserve native signaling and to reduce genetic complexity. As the equivalent residues have different numbers in *Vang*, as compared to the mouse or human orthologues, the mutations we investigated are referred by their numbers in *Drosophila*, here and throughout the paper, and are as follows: D317E, R321L, R332H, V391T, K418C and K577H (see [Figure 1B](#fig1){ref-type="fig"} for comparison to mammalian residue numbers).

In order to first test the contribution of individual mutations, we performed an overexpression experiment. Driving expression of wild-type (wt-)Vang with *actin-Gal4* (*ac \>WT*) led to a moderate hair reorientation phenotype ([Figure 2C and D](#fig2){ref-type="fig"}). This allowed us to compare whether mutations showed a gain- or loss-of-function phenotype with respect to the positive (wt-Vang) and negative (*Vang*^-/-^) control. A change or an increase in phenotype quality or strength as compared to wt-Vang overexpression could suggest a dominant negative effect or a gain-of-function in activity, while a decrease in strength would suggest a reduction in protein function or stability.

![Behavior of over-expressed *Drosophila* Vang carrying C-terminal mutations.\
(**A**) Overview of an adult wing highlighting the analyzed regions of hair reorientation. (**B**) Quantification of the percentage of actin hairs oriented within a specific angle range upon *actin-Gal4* driven overexpression (*ac\>*) of the different Vang mutant proteins and wild-type Vang. Also included for comparison is *Vang-/-* and *w^1118^* (a genetically wild-type wing that displays no phenotype). Graph is shown for region 1 (upper) and region 2 (lower). Angles from three independent wings were combined, and data binned to allow analysis using a *Chi*-squared test. \* indicates p\<0.001 (**C**) Example images of hair reorientation in region 1 in the indicated genotypes. Top panel shows adult wing, bottom panel shows the corresponding angles of hair orientation visualized through color (see 360 degree color scale, bottom right). Angles were determined using the Fuji plugin FijiWingsPolarity ([@bib21]). (**D**) Example images of hair reorientation in region 2. Left panel shows adult wing, and right panel the corresponding angles of hair orientation. (**E**) Western blot of wing disc lysates from the indicated genotypes. While similar levels of expression are observed, a difference in Vang mobility is notable for D317E, R321L and K577H, as indicated by blue arrows.\
Figure 2---source data 1.Raw data from the quantification of hair reorientation summarized in [Figure 2](#fig2){ref-type="fig"}.](elife-53532-fig2){#fig2}

Upon overexpression of wt-Vang, we observed consistent hair reorientation in specific regions of the wing. We therefore chose two regions that would be suitable for qualitative and quantitative analyses of the different mutants, with region 1 showing a more severe PCP phenotype as compared to region 2 ([Figure 2A](#fig2){ref-type="fig"}). Different mutations displayed different patterns of hair reorientation within these regions, confirming the system had an appropriate degree of sensitivity for this type of analysis. In region 1, D317E, R321L and K577H showed a distinct phenotype as compared to wt-Vang (over)expression. In fact, their hair pattern was more similar to that of *Vang^-/-^* wings or a genetically wild-type wing (*w^1118^*), included as a reference control that has no phenotype. In contrast, R332H, V391T and K418C all showed hair reorientation patterns similar to the gain-of-function (GOF) effect of wt-Vang overexpression ([Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). We also observed comparable changes in hair reorientation within region 2. In this case, D317E and K577H mirrored the phenotype of *Vang^-/-^*, while R321L showed similarity to the reference control (*w^1118^*). R332H, V391T and K418C again showed similar patterns to the GOF overexpression of wt-Vang ([Figure 2D](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}).

To quantify hair patterns, we utilized FijiWingsPolarity ([@bib21]), which determines the orientation of each hair within a given region, relative to the proximal-distal (P-D) axis. For visualization purposes, hair orientation angles are represented through arrows and a color gradient ([Figure 2C and D](#fig2){ref-type="fig"}). Through quantification of hair orientation angles, we were able to show that in region 1 all mutations with the exception of V391T had a significant alteration in hair reorientation as compared to wt-Vang overexpression, while in region 2 all mutations showed significant divergence from the wt-Vang ([Figure 2B](#fig2){ref-type="fig"}). To allow for statistical analysis, the data were pooled into three bins of angle orientation; normal orientation as determined by the reference control *w^1118^* (green), as well as a more anterior reorientation (yellow) or posterior reorientation (blue). The full spectrum of angles in 30° segments also reflected the changes in pattern ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}).

We confirmed that similar levels of protein expression were observed for each transgene (due to our experimental design). However, interestingly, D317E, R321L and K577H all showed a notable change in protein mobility ([Figure 2E](#fig2){ref-type="fig"}). This mobility shift was also observable in samples from *Vang-/-* tissue and in transfection experiments in S2 cells ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"} and Figure 4C). It has previously been demonstrated that Vang is phosphorylated leading to a mobility change and associated band shift on gels ([@bib37]; [@bib57]). Accordingly, phosphatase treatment altered wt-Vang mobility, but it did not impact any of the mutants suggesting that their phosphorylation is reduced or lost ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). As Vang phosphorylation is associated with membrane localization and function, this suggests that the D317E, R321L and K577H mutants are defective in one or both of these regards ([@bib37]; [@bib57]).

Dominant behavior and protein localization defects in the majority of mutations {#s2-3}
-------------------------------------------------------------------------------

To further investigate the effect of the respective mutation in the overexpression system, we analyzed protein localization in the pupal wing at \~25 hr APF, by which time wt-Vang is predominantly localized to the plasma membrane ([Figure 3B](#fig3){ref-type="fig"}). Besides comparing the localization of the mutants themselves, we also assessed any dominant effects by examining their effect on the localization of co-expressed wt-Vang. We expressed wt-Vang directly via the *actin* promoter (ac-Vang-GFP) within physiological levels throughout the whole wing blade/animal and simultaneously used *engrailed(en)-Gal4* to overexpress the transgenes in the posterior compartment of the wing ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). This allowed for comparison of the localization of wt-Vang-GFP in the anterior (control) vs. posterior (transgene expression) compartments.

![Overexpression of Vang transgenes affects localization of wild-type Vang.\
(**A**) Schematic showing regions of expression of different transgenes along the *Drosophila* wing blade. A direct *actin*-promoter driven (*ac-Vang-GFP*) construct is expressed at homeostatic levels throughout the wing blade, *engrailed-Gal4* drives expression of wild-type Vang-Flag or each of the associated mutant proteins in the posterior compartment of the wing. (**B**) Representative immunofluorescence images of regions from the anterior and posterior regions of a pupal wing overexpressing wild-type Vang-Flag in the posterior region. Note recruitment of Vang-Flag to the membrane in the posterior region (blue), and concomitant reduction in membrane localization of Vang-GFP in the posterior (blue) vs. anterior (red) compartment. The junctional marker PatJ shows consistent membrane labeling in both regions. (**C**) Representative immunofluorescence images of regions from the posterior compartment of pupal wings overexpressing the indicated Vang-Flag constructs. Note differences in localization of Vang-Flag mutants as compared to wild-type Vang (**B**), as well as altered wt-Vang-GFP localization. The junctional marker PatJ was unaffected in each case. (**D**) Regions of adult wing showing hair reorientation phenotypes in the indicated genotypes. Note the similarity in pattern between overexpression of WT, R332H, V391T and K418C mutants (swirls, cf. GOF in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), as compared to R321L (wild-type orientation), and D317E and K577H (downwards reorientation, cf. LOF in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) in posterior region of the wing. Color range is same as in [Figure 2](#fig2){ref-type="fig"}.](elife-53532-fig3){#fig3}

Overexpression of wt-Vang in the posterior compartment showed distinct membrane localization (as expected), visualized through Flag staining, while no signal was observed in the anterior compartment ([Figure 3B](#fig3){ref-type="fig"}). Vang-GFP (expressed from *ac-Vang-GFP*) also showed distinct membrane staining with levels reduced in the posterior compartment as compared to the anterior, suggestive of competition from the overexpressed Vang-Flag for membrane recruitment ([Figure 3B](#fig3){ref-type="fig"}). The junctional marker PatJ was unaffected by Vang expression ([Figure 3B](#fig3){ref-type="fig"}).

Consistent with their overexpression phenotypes, a number of changes to localization were observed for the different mutants. D317E and K577H were largely localized to the cytoplasm, and strikingly also altered the localization of wt-Vang-GFP in the posterior compartment ([Figure 3C](#fig3){ref-type="fig"}). In contrast, R321L behaved similarly to wt-Vang in both its localization and effect on Vang-GFP. R332H and K418C displayed a less distinct membrane localization that was echoed by diffuse Vang-GFP localization in the posterior compartment ([Figure 3C](#fig3){ref-type="fig"}). V391T showed distinct membrane localization with slightly increased membrane levels of Vang-GFP, as compared to controls ([Figure 3B and C](#fig3){ref-type="fig"}). In all cases, Vang-GFP and PatJ staining were unaffected in the anterior compartment ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}).

Overall, the localization data is consistent with our observed hair reorientation phenotypes, as well as protein mobility data ([Figure 2](#fig2){ref-type="fig"}). D317E and K577H behave like dominant negative, antimorph alleles. They cause hair reorientation patterns similar to *Vang^-/-^* ([Figure 3D](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). The similarity in pattern to *Vang*^-/-^ can be explained, as in these like in *Vang^-/-^* the protein is lacking from the membrane ([Figure 3C](#fig3){ref-type="fig"}). However, these mutants do not represent 'simple' LOF alleles, as they are dominantly affecting the localization of wt-Vang. R321L also displayed changes to protein mobility but did not lead to significant hair reorientation when overexpressed; its largely normal membrane localization and lack of effect on wt-Vang-GFP suggest it is a hypomorphic allele with reduced protein function ([Figures 2](#fig2){ref-type="fig"} and [3C](#fig3){ref-type="fig"}). R332H and K418C also appear to act in a dominant fashion, but in this case the protein is recruited to the membrane, where it could have a dominant effect on signaling ([Figure 3C](#fig3){ref-type="fig"}). In contrast, the staining of V391T and slight increase in accompanying Vang-GFP membrane localization suggest it may act as a mild GOF to enhance Vang signaling ([Figure 3C](#fig3){ref-type="fig"}).

Mutants show altered membrane localization in rescue conditions {#s2-4}
---------------------------------------------------------------

To confirm that the localization of the mutant proteins was not due to interference from endogenous Vang, we next assayed its localization in a *Vang^-/-^* background. Here, we used *actin*-Gal4 driven expression with which, due to the higher than endogenous expression levels of the transgenes (via the Gal4 amplification), we observed a gain-of-function phenotype with wt-Vang ([Figure 4A](#fig4){ref-type="fig"}). Despite this effect, we observed hair reorientation patterns in the absence of endogenous Vang that were consistent with the experiments described above. D317E and K577H displayed hair reorientation patterns similar to *Vang^-/-^*, while R332H, V391T and K418C showed a similar phenotype of hair orientation swirls as compared to overexpressed wt-Vang. Furthermore, R321L showed a more 'complete rescue', supporting its behavior as a hypomorph in protein function and thus a 'weaker GOF' phenotype, which resembles a better rescue of the *Vang*^-/-^ background ([Figure 4A](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}).

![NTD mutations affect membrane localization of Vang.\
(**A**) Regions 1 and 2 of the adult wing (see [Figure 2A](#fig2){ref-type="fig"}) showing hair reorientation phenotypes in the indicated genotype. Note similarity in pattern between WT, R332H, V391T and K418C mutants (swirls, cf. GOF in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), as compared to R321L (wild-type orientation), and D317E and K577H (downwards reorientation, cf. LOF in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Color range is same as in [Figure 2](#fig2){ref-type="fig"}. (**B**) Representative immunofluorescence images of pupal wings upon expression of Vang-Flag or indicated mutant Vang proteins using *actin-Gal4* driver. Note changes to Vang localization as shown through Flag staining (red), and the degree of overlap with actin (stained with Phalloidin, green) which marks the membrane (**C**) Western blot of wing discs from the indicated genotypes. Note that all transgenes were expressed at similar levels. Differences in mobility are also observed as in [Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.](elife-53532-fig4){#fig4}

Analysis of Flag staining for the transgenes revealed similar localization patterns as compared to the overexpression experiment in a wt control background ([Figure 3](#fig3){ref-type="fig"}). Wt-Vang localized distinctly at the membrane, indicated by an overlap with cortical actin stain ([Figure 4B](#fig4){ref-type="fig"}), while R321L and V391T showed slightly reduced and enhanced membrane localization, respectively. Furthermore, R332H and K418C displayed a diffuse membrane localization, and D317E and K577H failed to localize to the membrane ([Figure 4B](#fig4){ref-type="fig"}). We again confirmed that expression levels of each transgene were equivalent, and expected changes in protein mobility were detectable ([Figure 4C](#fig4){ref-type="fig"}).

Taken together, our data are consistent with the conclusions that D317E and K577H act as dominant-negative mutations with reduced membrane localization, while R332H and K418C act as dominant mutations that exert their effect at the membrane. R321L behaves like a hypomorph with reduced protein function, and V391T is a mild GOF enhancing protein function.

Rescue experiments in the eye confirm loss-of-function and gain-of-function behavior {#s2-5}
------------------------------------------------------------------------------------

To confirm and further refine the suggested mechanistic effects of mutations in altering Vang function, we analyzed their phenotype in the absence of endogenous Vang in an additional tissue. For this, we used the *Drosophila* eye, which shows generally weaker GOF effects with high expression levels of Vang as compared to the wing.

For consistency, we used *actin-Gal4* (*ac \>Vang*) to express the transgenes, and we also performed experiments with *sep-Gal4*, an eye specific driver related to and based on the *sevenless*/*sev* enhancer and promoter, that gives lower levels and spatially restricted expression ([@bib25]). PCP phenotypes in the eye are characterized by changes in ommatidial chirality as well as orientation ([Figure 5A](#fig5){ref-type="fig"}). Introduction of *ac \>Vang* Flag in the *Vang^-/-^* background resulted in a near perfect rescue with very minor chirality and orientation defects. As this phenotype was trending toward an overexpression phenotype of Vang, this suggested that the levels were just marginally too high for a complete rescue ([Figure 5B](#fig5){ref-type="fig"}). In contrast, due to its weaker expression *sep \>Vang* Flag showed only a partial rescue ([Figure 5B](#fig5){ref-type="fig"}). By comparing phenotypes with both Gal4 drivers, we were thus able to better ascertain how the mutants affected Vang function.

![*Vang-/-* rescue experiments with individual mutations reveal the nature of how they affect Vang function.\
(**A**) Schematic representation of the chiral forms of ommatidial clusters within the *Drosophila* eye. Dorsal chirality is represented by black arrows, ventral chirality by red arrows, and symmetrical (achiral) clusters by green arrows. The varying degree to which each cluster rotated during development is denoted by the angle of each arrow. (**B**) Quantification of the percentage of different chiral forms of clusters in the indicated genotypes (top). These include wild-type (WT), a flipped chiral form (Flip), or a symmetrical cluster (Sym.). Quantification of the percentage of misrotated clusters in the associated genotypes (bottom). Misrotation was split into three categories, mild is wild-type +/- 10 degrees, moderate is +/- 10--30 degrees from wild-type, and severe is +/- \> 30 degrees misrotation from wild-type. Note that rescue with *actin-Gal4* results in a mild overexpression phenotype due to the expression strength with this driver, (also [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), while *sep-Gal4* shows a weaker rescue due to its weaker and restricted (not all R-cells) expression. (**C**) Tangential eye sections of the region flanking the dorso-ventral midline (equator) in the indicated genotypes after rescue with *actin-Gal4* driver, anterior is left and dorsal is up. (**D**) Quantification of percentage of different chiral forms of clusters in the indicated genotypes (left). Quantification of percentage of misrotated clusters in the indicated genotypes (right). Data were analyzed using a *Chi*-squared test: \* indicates p\<0.001.\
Figure 5---source data 1.Raw data from the quantification of eye chirality and rotation defects summarized in [Figure 5](#fig5){ref-type="fig"}.](elife-53532-fig5){#fig5}

With both drivers, D317E and K577H showed very limited rescue in regards to chirality and only partial rescue in orientation, overall displaying a similar phenotype to *Vang^-/-^* ([Figure 5C,D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). This is consistent with their antimorphic nature; however, the partial rescue we observe suggests the mutants retain some activity. With *actin-Gal4*, R321L displayed a significantly better rescue of chirality (as compared to wt-Vang control), while with *sep-Gal4* the rescue was less efficient both in terms of chirality and orientation ([Figure 5C,D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Together this confirmed that R321L is a mild hypomorphic LOF allele and that the better rescue level observed with *ac-Gal4*, as compared to wt-Vang, is due to the higher expression levels. R332H showed a significant enhancement in chiral defects, as compared to control wt-Vang, with the *actin*-driver, as well as more significant orientation defects with the *sep*-driver. K418C showed a phenotype similar to wt-Vang ([Figure 5C,D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). While, V391T trended towards more severe chiral defects with the *actin*-driver, with a significantly better rescue of orientation with the *sep*-driver ([Figure 5C,D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Taken together with the wing data, this supports the notion that V391T is a mild hypermorph with GOF activity.

Mutations associated with reduced membrane localization or loss in protein function disrupt effector binding {#s2-6}
------------------------------------------------------------------------------------------------------------

Due to the defects associated with the different mutants, we wished to determine how they might affect effector binding. As many of the mammalian studies have focused on the interaction between Dishevelled (Dvl) and Vangl, we first examined the binding between Dsh and Vang, the *Drosophila* orthologues. We expressed wt-Vang-Flag and mutant constructs in S2 cells and tested for their interaction with Dsh-GFP by pull-down. D317E, R321L and K577H all showed a reduced ability to interact with Dsh-GFP ([Figure 6A](#fig6){ref-type="fig"}), while normal binding, comparable to wt-Vang, was observed for R332H, V391T and K418C ([Figure 6B](#fig6){ref-type="fig"}). Next we tested binding between the different Vang mutants and Prickle (Pk), the main effector and cytoplasmic interaction partner of Vang in vivo. The same pattern of binding was observed, with a reduction in binding to D317E, R321L and K577H, but no change with R332H, V391T and K418C ([Figure 6C and D](#fig6){ref-type="fig"}). This is consistent with the affected membrane association of the first three Vang mutations and our previous functional and phenotypic assertions (summarized in [Figure 6E](#fig6){ref-type="fig"}).

![Mutations associated with LOF phenotypes display reduced effector binding.\
(**A**) Western blot showing binding between Dsh-GFP and Vang-Flag wild-type or the indicated mutants. Note that Vang-Flag wild-type binds to Dsh-GFP but not the negative control Tctn-GFP. The D317E, R321L and K557H mutants show reduced binding as compared to wild-type Vang. (**B**) Western blot showing binding between Vang-Flag wild-type or the indicated mutants and Dsh-GFP. The Vang constructs are able to bind to Dsh to the same degree, while no binding is observed with Flag alone. (**C**) Western blot showing binding between Vang-Flag wild-type or the indicated mutants and Myc-Pk. The D317E, R321L and K577H mutants show a markedly weaker interaction with Myc-Pk as compared to wild-type Vang. (**D**) Western blot showing binding between Vang-Flag wild-type or the indicated mutants and Myc-Pk. The Vang constructs are able to bind Pk to the same degree. (**E**) Summary of the phenotypic outcome of investigated mutations, D, (cytoplasmic) and (membrane) distinguish between the two types of dominant mutations observed, which is based on their cellular localization. Colors are assigned based on different outcomes, also shown is the relative phenotypic strength of each mutation (see [Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). (**F**) Western blot showing the regions of Vang required for interaction with Dgo. Note that full-length Vang (1-584) and a construct containing residues 1--323 of Vang are able to interact with HA-Dgo. While a construct containing residues 1--303 does not interact, suggesting residues 304--323 in Vang are essential for its interaction with Dgo. (**G**) Schematic showing the C-terminal sequence of Vang, and human Vangl1 and Vangl2. Mutated residues are highlighted in colors associated with their phenotypic outcome as in E. Also highlighted are regions of Vang essential for its interaction with Dgo and Scribble, note their proximity to specific residues.](elife-53532-fig6){#fig6}

Furthermore, these interaction data suggest a trend whereby D317E, R321L and K577H all lead to a general reduction in effector binding. Interestingly, analyzing the location of these mutants along the C-terminal tail, they map in close proximity to regions of specific effector binding sites ([Figure 6G](#fig6){ref-type="fig"}). K557H is situated near to the PDZ binding motif which is involved in Scribble (Scrib) binding (Scrib is required for PCP and has been shown to interact with Vang in both mice and *Drosophila* \[[@bib15]; [@bib46]\]). We were able to show that Dgo binding requires amino acids 304--323 ([Figure 6F](#fig6){ref-type="fig"}) and D317E and R321L map within this region. As demonstrated, these mutations do not show specificity for a particular effector but instead a general reduction in binding. This correlation suggests that sites of effector binding along the C-terminal tail highlight regions of high sensitivity for Vang functionality, not just for binding to a particular effector, but in general for the integrity of the entire protein.

Discussion {#s3}
==========

Our analyses revealed a differential and causative behavior for the NTD-associated Vangl mutants. *Drosophila* provides unprecedented depth to the analysis of PCP in the respective mutations through its well-established and detailed in vivo PCP features, the possibilities to study the NTD-mutations in an otherwise wild-type background as well as in the *Vang-/-* context, and both quantitative and qualitative nature of the assays for PCP. Taken together, our data revealed that the mutations analyzed fall into different functional categories and that all patient derived mutations tested are indeed causative of PCP defects, and hence likely causative of NTD in the patients.

Functional definition of both dominant negative and gain-of-function mutations {#s3-1}
------------------------------------------------------------------------------

The detailed analyses of the NTD-associated mutations revealed specific functional features. For example, the R321L mutation (all numbers refer to the residues in *Drosophila* Vang, see [Figure 1](#fig1){ref-type="fig"} for the respective numbers in mouse and human, unless otherwise indicated) behaves like a mild hypomorphic LOF allele, as demonstrated largely by a lack of phenotype upon over-expression and through the level of rescue observed. This is consistent with data from the *Vangl2^Lp^*-R259L mouse, where only mild NTD defects were observed, along with no difference in membrane localization or levels ([@bib30]). In our system, besides reduced membrane localization, we also observed its aberrant mobility in western blot assays, an indication that functionality of the protein was decreased, as well as diminished ability to bind effectors. Differences in protein mobility, localization, and effector binding were also observed for D317E and K577H. In contrast to R321L, however, both mutants failed to localize to the membrane, which was reflected in a hair orientation phenotype reminiscent of a *Vang^-/-^* wing. Furthermore, both mutants showed largely no rescue in the respective assays. D317E displayed a stronger phenotype as compared to K577H, which correlated with the severity of subcellular mislocalization, highlighting the sensitivity and accuracy of the *Drosophila* assays.

Expression of D317E and K577H transgenes also led to mislocalization of wild-type Vang, revealing mechanistic insight into the dominant nature of these mutations. For D317E, this is consistent with data from the mouse (D255E), with our data further demonstrating that the mutation does indeed act in a dominant negative manner. It was previously demonstrated that Sec24b promotes the selective sorting of Vangl2 into vesicles for ER to Golgi transport, and that the *Vangl2^Lp(D255E)^* allele fails to undergo this process ([@bib44]). It has been demonstrated that the *Vangl2^Lp^* mouse shows reduced membrane protein levels, thought to result from the protein becoming trapped in the ER and subsequently targeted for degradation. While this might suggest a 'simple' LOF phenotype, the ability of Vangl1 and Vangl2 to interact complicates matters ([@bib72]). Further, it was demonstrated that Vangl1 is missing from the membrane in *Vangl2^Lp^* mice but not in a *Vangl2* knock-out, with *Vangl2^Lp^* also displaying a more severe phenotype ([@bib55]; [@bib72]). Additionally, a dominant effect was observed in regard to the phosphorylation of wild-type Vangl2, which was reduced upon co-expression of the *Vangl2^Lp^* mutant ([@bib27]). This is consistent with - and reminiscent of - our dominant relocalization observations and, due to the hair reorientation pattern caused in our experiments, our data support the rationale that the original *Vangl2^Lp^* alleles are dominant negative mutations and not LOF. This is in alignment with the original genetic studies performed in the mouse that proposed semi-dominance ([@bib13]; [@bib56]).

The patient derived K577H mutation had not previously been investigated. Here, we demonstrate that it is causative for PCP defects, and interestingly showed mechanistic similarity to D317E (the original *Vangl2^Lp^* mutation, see above), functioning like a dominant negative. Therefore, our data provide a link between the NTD mouse mutations and a human mutation and support the idea that mutations that affect PCP signaling in distinct ways could all contribute to NTD pathology. In line with this notion, we also observed that R332H and K418C displayed dominant activity in functional assays, consistent with the hypothesis that they are also causative in NTD. However, their phenotypic impact was different. These mutants retained effector binding and were localized to the membrane, even if not as distinctly as wild-type Vang. Additionally, the hair re-orientation phenotype observed was reminiscent of a GOF effect of Vang, which results from the non-polar localization of core PCP proteins at the membrane. As their interaction with cytoplasmic effectors and phosphorylation appear to be retained, this points to R332H and K418C behaving as hypermorphs with an effect on the PCP signaling complexes at the membrane. However, due to the relatively high expression levels of our transgenes we were not able to find conditions to analyze changes to protein asymmetry. Nonetheless, taken together and most importantly, the above-mentioned human patient mutations, cause dominant PCP defects, K577H with a dominant negative function, and R332H and K418C as hypermorphic alleles, and thus are likely causative of the NTDs.

Finally, we obtained data suggestive of V391T functioning as a mild hypermorph GOF. Although in the majority of assays V391T behaved similarly to R332H and K418C, its membrane localization appeared more robust, and rescue experiments were suggestive of the mutation leading to a milder GOF, and not dominant behavior, as was seen with R332H and K418C. Nonetheless, the data for this human mutation is again consistent with it also being causative of NTD.

*Drosophila* as model to define causative nature of human mutations {#s3-2}
-------------------------------------------------------------------

While there are caveats of using any specific system, including *Drosophila*, the ability to phenocopy and refine results suggested from the mouse, for example in the case of the original *Vangl2^Lp^*, and to demonstrate sensitivity through quantitative analyses, highlights its utility in exploring the functionality and potential causative nature of human NTD-associated mutations. In fact, our assays were both able to reveal additional functional insight into mutations that had been studied previously by other means and to define functional and mechanistic behavior of previously unstudied human mutations. A popular system to investigate the different mutations is to analyze their localization in MDCK cells. In this assay, the mouse *Vangl2^Lp^* allele, D255E, was detected within the ER, and showed reduced stability and proteosomal degradation, echoing phenotypes from the mouse ([@bib29]). The same assay also showed defective localization for S464N, R259L and R274Q (equivalent to R332H in our assay), with all mutations displaying very similar phenotypes ([@bib34]; [@bib33]). While a useful assay to reveal potentially damaging effects upon *Vangl1*/2, it does not capture the true nature of the mutation as our in vivo assays do. For example, R259L is milder in phenotype as compared to S464N and displays membrane localization in vivo, which is not captured in the MDCK assay. In contrast, our assays capture these features in the *Drosophila* in vivo system. Furthermore our results define that R274Q/R270H in *hVANGL1*/2, respectively (R332H in *Drosophila*), likely has dominant negative activity. The result in MDCK cells for both R259L and R274Q is also at odds with experiments performed in zebrafish. Both mutants behaved similarly to wild-type protein in overexpression and rescue experiments ([@bib30]; [@bib51]). The lack of phenotype from the zebrafish experiments suggests that, while suitable for mutations that have a strong pathological effect, this system may not be sensitive enough to reveal phenotypic and functional insight with milder mutations.

In line with this hypothesis, the zebrafish system did show phenotypic behavior for the *Vangl2^Lp^* mutations, mouse D255E and S464N, and additionally human M328T, with all performing as LOF in assays in the fish ([@bib51]). Our data also revealed that mouse D255E (D317E in *Drosophila*) displayed LOF characteristics, for example diminished effector binding. However, our assays allow us to conclude further, as discussed above, that the mutant displays dominant negative function. In contrast, our data are not consistent with the zebrafish findings for human M328T. The equivalent *Drosophila* mutant, V391T, displayed a mild GOF phenotype. This residue was the least conserved among the mutations tested, and while it is methionine in human and mouse Vangl1, the equivalent residue is valine in mouse, human and frog Vangl2, as well as in *Drosophila* Vang. The differences in phenotypic outcome may be due to this discrepancy, and thus investigating the phenotypic behavior of Vangl2 with an equivalent mutation in a mammalian assay could provide further insight. This result also implies, as is to be expected, that the most conserved residues between systems will give the most reliable functional insight. Nonetheless, we were able to define that a mutation at this residue causes a dominant PCP defect, suggesting its importance for overall Vang function in PCP in general and NTD in particular.

As discussed above, our data set reveals graded phenotypes in vivo, with different mutations displaying more or less severe PCP defects. However, we could not find a pattern to correlate the severity observed with features of the different residues, for example, whether they occurred originally in *VANGL1* vs. *VANGL2*, if the substitution was more conservative or drastic, or whether familial or sporadic. This suggests that it is the location of the residue that exhibits a mutational change as the most important factor in determining phenotypic strength. A prime example of this is the comparison of the two mouse *Vangl2^Lp^* alleles with a conservative substitution D255E and more drastic substitution R259L. While they are located in a similar region, the closer proximity of D255E downstream of the transmembrane domain, which also correlates with the Dgo interaction region, suggests it is a functionally more important residue and site, for protein integrity. Consistent with this notion, our observations that the mutations that display LOF characteristics, D255E, R259L and K577H, all map close to regions of effector binding, suggest that these regions are important for the general functional and structural integrity of Vang family proteins. While we cannot rule out that the reduced binding observed for D317E and K577H is due to their mislocalization and inaccessibility to effector proteins, this is clearly not the case for R321L which is localized to the membrane. We therefore favor the above hypothesis and believe these mutants lead to a general structural defect. While many of the NTD mutations may interfere with Vang/Vangl function by affecting its structure, it is also possible that they hit as yet unknown motifs or sites of post-translational modification. For example, R274/270, in human *VANGL1/2*, respectively (R332 in *Drosophila*), forms part of a putative D-box ubiquitination motif ([@bib34]), and two mutations found in the N-terminus of human patients are mapped to phosphorylation sites important for Vang function ([@bib27]; [@bib40]; [@bib42]). Overall, this suggests that there is much more to be revealed in determining both the contribution of PCP mutants to NTD, and that analyzing such NTD-associated mutations will reveal important mechanistic insight into Vang/Vangl function in general, in both developmental and disease contexts.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                       Designation                         Source or\                                            Identifiers                                                    Additional\
  (species) or\                                                                           reference                                                                                                            information
  resource                                                                                                                                                                                                     
  --------------------------------------------------- ----------------------------------- ----------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------------------------------------------
  Gene (*Drosophila melanogaster*)                    *Vang*                              Pubmed ID: 35922                                      Dmel_CG807, CG8075, Dmel\\CG8075, Stbm, Strabismus, Van Gogh   Chromosome 2R,\
                                                                                                                                                                                                               NT_033778.4 (9103238...9106796)

  Genetic reagent (*Drosophila melanogaster*)         *w\[1118\]*                         FlyBase ID:\                                                                                                         Reference control
                                                                                          FBal0018186                                                                                                          

  Genetic reagent (*Drosophila melanogaster*)         *Vang\[6\]*                         Bloomington*Drosophila*Stock Center                   6918                                                           Null allele

  Genetic reagent (*Drosophila melanogaster*)         *UAS-Vang- Flagx3*                  This Paper                                                                                                           Insertion into BDSC stock 9752 - PBAC{yellow\[+\]-attP-3B}VK00037\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Genetic reagent (*Drosophila melanogaster*)         *UAS-Vang-D317E-Flagx3*             This Paper                                                                                                           Insertion into BDSC\
                                                                                                                                                                                                               stock 9752 - PBAC{yellow\[+\]-attP-3B}VK00037\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Genetic reagent (*Drosophila melanogaster*)         *UAS-Vang-R321L-Flagx3*             This Paper                                                                                                           Insertion into BDSC stock 9752 - PBAC{yellow\[+\]-\
                                                                                                                                                                                                               attP-3B}VK00037\
                                                                                                                                                                                                               Can be obtained from\
                                                                                                                                                                                                               Mlodzik Laboratory, ISMMS

  Genetic reagent (*Drosophila melanogaster*)         *UAS-Vang-R332H-Flagx3*             This Paper                                                                                                           Insertion into BDSC stock 9752 - PBAC{yellow\[+\]-attP-3B}VK00037\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Genetic reagent (*Drosophila melanogaster*)         *UAS-Vang-*\                        This Paper                                                                                                           Insertion into BDSC stock 9752 - PBAC{yellow\[+\]-attP-3B}VK00037\
                                                      *V391T-Flagx3*                                                                                                                                           Can be obtained from Mlodzik Laboratory, ISMMS

  Genetic reagent (*Drosophila melanogaster*)         *UAS-Vang-K418C-Flagx3*             This Paper                                                                                                           Insertion into BDSC stock 9752 - PBAC{yellow\[+\]-attP-3B}VK00037\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Genetic reagent (*Drosophila melanogaster*)         *UAS-Vang-K577H-Flagx3*             This Paper                                                                                                           Insertion into BDSC stock 9752 - PBAC{yellow\[+\]-attP-3B}VK00037\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Genetic reagent (*Drosophila melanogaster*)         *Vang\[6\],UAS-Vang-Flagx3*         This Paper                                                                                                           Recombined stock\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Genetic reagent (*Drosophila melanogaster*)         *Vang\[6\],UAS-Vang-D317E-Flagx3*   This Paper                                                                                                           Recombined stock\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Genetic reagent (*Drosophila melanogaster*)         *Vang\[6\],UAS-Vang-R321L-Flagx3*   This Paper                                                                                                           Recombined stock\
                                                                                                                                                                                                               Can be obtained from\
                                                                                                                                                                                                               Mlodzik Laboratory, ISMMS

  Genetic reagent (*Drosophila melanogaster*)         *Vang\[6\],UAS-Vang-R332H-Flagx3*   This Paper                                                                                                           Recombined stock\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Genetic reagent (*Drosophila melanogaster*)         *Vang\[6\],UAS-Vang-V391T-Flagx3*   This Paper                                                                                                           Recombined stock\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Genetic reagent (*Drosophila melanogaster*)         *Vang\[6\],UAS-Vang-K418C-Flagx3*   This Paper                                                                                                           Recombined stock\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Genetic reagent (*Drosophila melanogaster*)         *Vang\[6\],UAS-Vang-K577H-Flagx3*   This Paper                                                                                                           Recombined stock\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Genetic reagent (*Drosophila melanogaster*)         *actin-Gal4*                        Bloomington*Drosophila*Stock Center                   3954                                                           

  Genetic reagent (*Drosophila melanogaster*)         *ac-Vang-GFP*                       Gift from David Strutt, University of Sheffield, UK                                                                  

  Genetic reagent (*Drosophila melanogaster*)         *en-Gal4*                           Bloomington*Drosophila*Stock Center                   1973                                                           

  Genetic reagent (*Drosophila melanogaster*)         *sep-Gal4*                          ([@bib25])                                                                                                           

  Cell line (*Drosophila melanogaster*)               S2                                  Thermo Fisher Scientific                              69007                                                          Stock tested for contamination, characterized by isozyme and karyotype analysis

  Transfected construct (*Drosophila melanogaster*)   pUAS-Vang-Flagx3                    This Paper ([@bib7])                                  pUASTattB vector                                               Cloned using NotI-XbaI\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Transfected construct (*Drosophila melanogaster*)   pUAS-Vang-D317E-Flagx3              This Paper                                                                                                           Made using SDM\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Transfected construct (*Drosophila melanogaster*)   pUAS-Vang-\                         This Paper                                                                                                           Made using SDM\
                                                      R321L-Flagx3                                                                                                                                             Can be obtained from Mlodzik Laboratory, ISMMS

  Transfected construct (*Drosophila melanogaster*)   pUAS-Vang-\                         This Paper                                                                                                           Made using SDM\
                                                      R332H-Flagx3                                                                                                                                             Can be obtained from Mlodzik Laboratory, ISMMS

  Transfected construct (*Drosophila melanogaster*)   pUAS-Vang-V391T-Flagx3              This Paper                                                                                                           Made using SDM\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory,\
                                                                                                                                                                                                               ISMMS

  Transfected construct (*Drosophila melanogaster*)   pUAS-Vang-K418C-Flagx3              This Paper                                                                                                           Made using SDM\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Transfected construct (*Drosophila melanogaster*)   pUAS-Vang-K577H-Flagx3              This Paper                                                                                                           Made using SDM\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Transfected construct (*Drosophila melanogaster*)   pAc5.1-Gal4                         Gift from Andreas Jenny, AECOM, USA                                                                                  

  Transfected construct (*Drosophila melanogaster*)   pAc5.1-Dsh-GFP                      ([@bib52])                                                                                                           

  Transfected construct (*Drosophila melanogaster*)   pAc5.1-Myc-Pk                       Gift from Andreas Jenny, AECOM, USA                                                                                  

  Transfected\                                        pAc5.1-HA-Dgo                       Gift from Andreas Jenny, AECOM, USA                                                                                  
  construct (*Drosophila melanogaster*)                                                                                                                                                                        

  Transfected construct (*Drosophila melanogaster*)   pTub-Tctn-GFP                       This Paper                                            pCaSpeRTubGFP vector with pUAST MCS                            Cloned using BglII-XhoI\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Transfected construct (*Drosophila melanogaster*)   pAc5.1-Flagx3                       Gift from Andreas Jenny, AECOM, USA                                                                                  

  Transfected construct (*Drosophila melanogaster*)   pAc5.1-Flag-Vang                    This Paper                                            pAc5.1-Flag vector                                             Cloned using NotI-XbaI\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Transfected construct (*Drosophila melanogaster*)   pAc5.1-Flag-\                       This Paper                                            pAc5.1-Flag vector                                             Cloned using NotI-XbaI\
                                                      Vang 1--323                                                                                                                                              Can be obtained from Mlodzik Laboratory, ISMMS

  Transfected construct (*Drosophila melanogaster*)   pAc5.1-Flag-Vang-1--303             This Paper                                            pAc5.1-Flag vector                                             Cloned using NotI-XbaI\
                                                                                                                                                                                                               Can be obtained from Mlodzik Laboratory, ISMMS

  Antibody                                            Flag                                Sigma Aldrich                                         M2                                                             1:5000 IB/I:50 IF

  Antibody                                            Gamma-\                             Sigma Aldrich                                         GTU-88                                                         1:1000
                                                      Tubulin                                                                                                                                                  

  Antibody                                            GFP                                 Roche                                                 7.1 and 13.1                                                   1:1000

  Antibody                                            GFP                                 Invitrogen                                            A11122                                                         1:100

  Antibody                                            PatJ                                Gift from Jun Wu, ISMMS, USA                                                                                         1:500

  Antibody                                            Myc                                 Santa Cruz Biotechnology                              9E10                                                           1:1000

  Antibody                                            HA                                  Roche                                                 3F10                                                           1:1000

  Sequence-\                                          D317E                               GATCATTCGCTCCCCGGAAGGCGTTTCGCGCTCCTAC                                                                                PCR primer
  based\                                                                                                                                                                                                       
  reagent                                                                                                                                                                                                      

  Sequence-based\                                     R321L                               GACGGCGTTTCGCTCTCCTACATGTTG                                                                                          PCR primer
  reagent                                                                                                                                                                                                      

  Sequence-\                                          R332H                               GTCAGCTGAGCATCCAACATGCGGCTGTGTGGGTGCTAC                                                                              PCR primer
  based\                                                                                                                                                                                                       
  reagent                                                                                                                                                                                                      

  Sequence-\                                          V391T                               CCAGAGTCGAGCAACTCTAGCAGCCAACG                                                                                        PCR primer
  based reagent                                                                                                                                                                                                

  Sequence-based\                                     K418C                               GTACGAACGTCGTGTGTGTAAACGGCGTGCCCGTC                                                                                  PCR primer
  reagent                                                                                                                                                                                                      

  Sequence-based reagent                              K577H                               AAGCAACAAATTTGTTCTTCACTTGAACTCCGAAACATCC                                                                             PCR primer

  Sequence-based reagent                              TCTN-f                              GGAAGATCTATGAAGGAAGTG                                                                                                PCR primer

  Sequence-based reagent                              TCTN-r                              CCGCTCGAGGCAAAGTTG                                                                                                   PCR primer

  Sequence-based reagent                              Vang-f                              TATGCGGCCGCTCATGGAAAACGAATCCGTC                                                                                      PCR primer

  Sequence-based reagent                              Vang-584-r                          ATATCTAGATTATACGGATGTTTCGGAGTT                                                                                       PCR primer

  Sequence-based reagent                              Vang-323-r                          ATATCTAGATTAGTAGGAGCGCGAAACGCC                                                                                       PCR primer

  Sequence-based reagent                              Vang-303-r                          ATATCTAGATTAGTGTCGCAGCTCTAGTAA                                                                                       PCR primer

  Commercial assay or kit                             Effectene                           Qiagen                                                301427                                                         

  Commercial assay or kit                             GFP-Trap Agarose                    Chromotek                                             gta                                                            

  Software, algorithm                                 FijiWingsPolarity                   ([@bib21])                                                                                                           

  Other                                               Lambda Protein Phosphatase          NEB                                                   P0753S                                                         
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Fly strains {#s4-1}
-----------

Flies were raised on standard medium, and maintained at 25**°**C unless otherwise stated. To generate *UAS-Vang-Flagx3* transgenic flies, Vang-Flagx3 ([@bib37]) was PCR-amplified using phusion high-fidelity DNA polymerase (Thermo Scientific) and cloned into the pUAST-attB vector ([@bib7]) using NotI-XbaI sites. Point mutants were created using site-directed mutagenesis, the primers used can be found in the key resources table.

Plasmids were verified by Sanger sequencing (GENEWIZ) and sent to BestGene Inc for insertion into BDSC stock number 9752 - *PBAC{yellow\[+\]-attP-3B}VK00037.*

S2 culture, pull-downs, and immunoblotting {#s4-2}
------------------------------------------

S2 cells were grown according to standard procedures in Schneider's Medium (Gibco) supplemented with 10% heat-inactivated Fetal Bovine Serum (Gibco). Effectene (QIAGEN) was used to transfect plasmids into S2 cells according to manufacturer's protocols. For details of constructs used please refer to the key resources table. Cells were transfected for \~48 hr before lysis in buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA and 1% Triton-X-100.

For pull-down experiments with Flag, 10 μl of anti-Flag M2 affinity gel was used per sample (Sigma Aldrich). Lysates were incubated with affinity gel at 4**°**C, followed by two washes with buffer containing 50 mM Tris-HCl pH 7.5, 350 mM NaCl, 1 mM EDTA and two washes with buffer containing 50 mM Tris-HCl pH 7.5, 500 mM NaCl, 1 mM EDTA, 0.1% SDS. For GFP pull-down, GFP-Trap agarose was used (Chromotek). In this case, cells were lysed in buffer containing; 10 mM Tris-HCl pH7.5, 150 mM NaCl, 0.5 mM EDTA, and 1% Triton-X-100. This was diluted prior to agarose incubation as per the manufacturer's protocol. Lysates were incubated with 20 μl agarose at 4**°**C followed by four washes with buffer containing 10 mM Tris-HCl pH7.5, 350 mM NaCl, 0.5 mM EDTA. For both pull-downs, samples were eluted through boiling at 95**°**C in 5x final sample buffer. Wing discs were dissected from third instar larvae and lysates prepared by boiling collected discs at 95**°**C in 5x final sample buffer. To perform phosphatase treatment, lysates were exposed to lambda protein phosphatase (NEB) for 30 min at 30**°**C.

Lysates were resolved by polyacrylamide gel electrophoreses and transferred to nitrocellulose membrane. The primary antibodies and concentration used for immunoblotting can be found in the key resources table. HRP conjugated secondary antibodies were used at 1:5000 (Jackson ImmunoResearch Laboratories).

*Drosophila* dissection and immunohistochemistry {#s4-3}
------------------------------------------------

Adult wings were collected in PBS containing 0.1% Triton-X-100 (PBST) and incubated for 1 hr at room temperature before mounting in 80% glycerol in PBS. Pupal wings were dissected and fixed in 4% paraformaldehyde containing 0.1% Triton-X-100 for 45 mins--1 hr. Tissue was washed with PBST twice and incubated in 5% donkey or goat serum containing PBST for 15 min. Primary antibodies were added and tissue incubated overnight at 4**°**C. Tissue was washed three times with PBST before incubation with fluorescent secondary antibodies and phalloidin diluted in 5% serum PBST for 2--4 hr at room temperature. Samples were washed four times with PBST and mounted in Vectashield media (Vector Labs). Primary antibodies used are listed in the key resources table. Secondary antibodies were from Jackson ImmunoResearch Laboratories (1:200) and Phalloidin from Molecular Probes (1:1000). Eye sections were prepared as previously described ([@bib26]), and eyes were sectioned near the equatorial region for analysis.

Imaging, quantification and statistical analysis {#s4-4}
------------------------------------------------

Imaging of adult wings and eye sections was performed on a Zeiss Axioplan microscope, imaging of pupal wings was carried out on either a Leica SP5 or Zeiss 880 confocal microscope. Hair reorientation angles were quantified using the FijiWingsPolarity plugin, details of which can be found in [@bib21]. To perform the quantification, equivalent regions were cropped from three wings in each genotype. Angles of polarity were determined utilizing the plugin and the angles from each genotype combined. For statistical analysis, angles were divided into three categories: anterior reorientation, wild-type, and posterior reorientation. This satisfied the conditions of a valid *Chi*-squared test. Adult eye sections were assigned chirality by hand and orientation angle was defined using ImageJ. For statistical analysis, a *Chi*-squared test was performed.

Experimental design {#s4-5}
-------------------

In all cases, experiments were performed on at least 3 distinct occasions to ensure technical replication. To ensure biological replication for experiments involving *Drosophila* tissue, 3--10 individual flies were examined for phenotypic similarity. All images and blots within the study were selected as the most representative of the population or findings after this analysis. This approach and sample size is consistent with previous studies performed in our laboratory that have generated reproducible data.

Statistical analysis {#s4-6}
--------------------

In all cases, unless otherwise stated a Chi-square test was performed. This analysis was performed as it is an accepted test for differences between binned distributions as is the case for our data, and so our analysis examined whether we could disprove to a certain level of significance, the null hypothesis that two data sets are drawn from the same population distribution function. For analysis of actin rotation due to the low values in the medium and severe categories these categories were combined and a Fisher's exact test was performed. The Fisher's exact test was performed in place of the Chi-square test as the low sample size in specific categories meant conditions of the latter would not be satisfied leading to inaccurate analysis. All analyses were done using Prism software and N value and p values are detailed in tables below.

  [Figure 2B](#fig2){ref-type="fig"} - Region 1   p value    [Figure 2B](#fig2){ref-type="fig"} - Region 2   p value
  ----------------------------------------------- ---------- ----------------------------------------------- ----------
  ac \> WT vs. ac \> D317E                        \<0.0001   ac \> WT vs. ac \> D317E                        \<0.0001
  ac \> WT vs. ac \> R321L                        \<0.0001   ac \> WT vs. ac \> R321L                        \<0.0001
  ac \> WT vs. ac \> R332H                        \<0.0001   ac \> WT vs. ac \> R332H                        \<0.0001
  ac \> WT vs. ac \> V391T                        0.1083     ac \> WT vs. ac \> V391T                        \<0.0001
  ac \> WT vs. ac \> K418C                        \<0.0001   ac \> WT vs. ac \> K418C                        \<0.0001
  ac \> WT vs. ac \> K577H                        \<0.0001   ac \> WT vs. ac \> K577H                        \<0.0001

  [Figure 2B](#fig2){ref-type="fig"}   Region 1 N   Region 2 N
  ------------------------------------ ------------ ------------
  Vang -/-                             188          739
  W1118                                118          507
  WT                                   204          588
  D317E                                111          581
  R321L                                167          609
  R332H                                142          658
  V391T                                157          619
  K418C                                150          538
  K577H                                117          648

  [Figure 5D](#fig5){ref-type="fig"}- Chirality   p value    [Figure 5D](#fig5){ref-type="fig"} - Rotation   p value
  ----------------------------------------------- ---------- ----------------------------------------------- ----------
  ac \> WT vs. ac \> D317E                        \<0.0001   ac \> WT vs. ac \> D317E                        \<0.0001
  ac \> WT vs. ac \> R321L                        0.0267     ac \> WT vs. ac \> R321L                        0.3948
  ac \> WT vs. ac \> R332H                        0.0004     ac \> WT vs. ac \> R332H                        0.2055
  ac \> WT vs. ac \> V391T                        0.068      ac \> WT vs. ac \> V391T                        0.2481
  ac \> WT vs. ac \> K418C                        0.2935     ac \> WT vs. ac \> K418C                        0.0017
  ac \> WT vs. ac \> K577H                        \<0.0001   ac \> WT vs. ac \> K577H                        0.0015

  [Figure 5D](#fig5){ref-type="fig"}   Chirality - N   Rotation - N
  ------------------------------------ --------------- --------------
  Vang -/-                             526             177
  WT                                   226             146
  D317E                                354             151
  R321L                                491             134
  R332H                                218             123
  V391T                                812             105
  K418C                                667             143
  K577H                                768             171

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"} -\   p value    [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"} -\   p value
  Chirality                                                                  Rotation                                                        
  --------------------------------------------------------------- ---------- --------------------------------------------------------------- ----------
  ac \> WT vs. ac \> D317E                                        \<0.0001   ac \> WT vs. ac \> D317E                                        0.0003

  ac \> WT vs. ac \> R321L                                        0.0225     ac \> WT vs. ac \> R321L                                        0.0048

  ac \> WT vs. ac \> R332H                                        0.1896     ac \> WT vs. ac \> R332H                                        0.0001

  ac \> WT vs. ac \> V391T                                        0.2827     ac \> WT vs. ac \> V391T                                        \<0.0001

  ac \> WT vs. ac \> K418C                                        0.1779     ac \> WT vs. ac \> K418C                                        0.5566

  ac \> WT vs. ac \> K577H                                        0.0043     ac \> WT vs. ac \> K577H                                        0.0267
  -----------------------------------------------------------------------------------------------------------------------------------------------------

  [Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}   Chirality - N   Rotation - N
  ------------------------------------------------------------ --------------- --------------
  Vang -/-                                                     365             100
  WT                                                           325             89
  D317E                                                        312             112
  R321L                                                        203             101
  R332H                                                        234             125
  V391T                                                        266             127
  K418C                                                        428             134
  K577H                                                        348             118
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

By modeling human and mice mutations of Van Gogh, a planar cell polarity gene, in *Drosophila*, your work provides interesting mechanistic data into how these variants contribute to neural tube defects.

**Decision letter after peer review:**

Thank you for submitting your article \"Mutations associated with human neural tube defects display disrupted planar cell polarity in *Drosophila*\" for consideration by *eLife*. Your article has been reviewed by Marianne Bronner as the Senior Editor, Hugo Bellen as the Reviewing Editor, and three reviewers. We apologize for the lengthy review process but the holidays did not help. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. Please address the concerns of reviewer one and where possible those of reviewers 2 and 3.

We are enclosing the unedited version of the three reviewers comments, as they had some disagreements between them to which we wanted you to be privy. However, after discussion, the reviewers agreed that your paper is suitable for publication in *eLife* but that it will require extensive editing to make it more reader friendly for a broad audience (rather than just Drosophilists), and that it is better polished. Note that in the future, a more sophisticated approach should be envisaged using CRISPR technology and that point mutations in the endogenous gene will become the norm, rather than overexpression studies.

Reviewer \#1:

I quite like this new paper, which attacks the knotty problem of assessing pathogenicity within the rapidly expanding universe of disease associated variants from human patients. NTDs are an important problem, and the PCP genes are well known to be associated with NTDs. However, for the vast majority of variants we have little information relating genotype to phenotype. Here, the authors exploit the unique advantages of the *Drosophila* system to assess the pathogenicity of several variants in Vangl. The paper is very important, then, for developing a new system in which such pathogenicity can be assessed in the biologically relevant setting of a planar polarized epithelium. It therefore lays down the groundwork for systematic assessment of PCP variants in human disease.

That said, the paper suffers from being inaccessible to non-Drosopholists and for providing too little context for the findings. With more effort put into the writing, this paper would be an excellent fit for *eLife*.

Comments, in order of appearance in the manuscript:

1\) Improved scholarship would help: The significance of this paper rests in the synthesis of ideas and the integration of scientific communities (i.e. It exploits model system (fly) genetics to understand human disease genetics). To be effective, then, the paper must not alienate any of the stakeholders. So, the biggest liability is the paper\'s failure to meaningfully deal with the literature outside of the fly. This must be corrected:

Introduction. It\'s not clear why the Kibar 2007 paper is cited here. It is not a review of NTDs, but rather a primary paper showing for the first time the Vangl2 is mutated in human NTDs. It would more properly be cited in passages linking Vangl2 to NTDs (i.e. later in the Introduction).

Introduction. Several errors: Tada and Smith, 2000 did not look at neutral tube closure or neural tissue at all. It should be removed. Wallingford et al., 2002 is a review of PCP and convergent extension and does not mention neural tube closure in any depth; this should be replaced with the relevant paper for the link to neural plate width, which is Wallingford and Harland, 2002. Likewise, while the Wang, 2006b reference does describe PCP genes and neural tube closure, Wang, 2006a is the paper that actually links PCP to neural plate width. It should be cited here.

Introduction: Wang, 2006b should be included in the list here.

Introduction: The Looptail mouse was studied by geneticists for decades before it was identified as a mutation in Vangl2. That work is notable because the odd penetrance of the allele led to the conclusion that the mutation was \"semi-dominant,\" a decades-old conclusion confirmed by the nice experiments here. I recommend the authors discuss and cite (at a minimum) the following:

Developmental basis of severe neural tube defects in the loop-tail (Lp) mutant mouse: use of microsatellite DNA markers to identify embryonic genotype.

Copp, Checiu and Henson, 1994.

All-or-none craniorachischisis in Loop-tail mutant mouse chimeras.

Musci and Mullen, 1990.

Strong and Hollander, (1949).

These papers might also be re-introduced in the Discussion section.

The Introduction almost seems to be specifically designed to irritate non-Drosophilists. One might read a passage like this and retort that the linkage of PCP to NTDs is really the only truly important PCP finding, and it was made in the mouse. Why risk it?

2\) Not written accessibly: I was able eventually to figure out what was what in Figure 2, but this critical figure was very poorly described.

Subsection "*Drosophila* provides a sensitive system for investigating the effect of mutations on PCP", I don\'t know know what \"attP/B sites\" are, would nice to have this system explained.

Figure 2. I do not know what *w1118* is. After some digging, I find it is the control. But then, why is it shown after the mutant? What are we meant to compare the others to? The mutant or the control?

Figure 2. \"ac\>\" is never explicitly defined, though I gather it means the actin-Gal4 driven construct.

Figure 2. All the text in B is unreadably small.

Subsection "*Drosophila* provides a sensitive system for investigating the effect of mutations on PCP": The text says \"all showed a notable change in protein mobility, but the data in Figure 2C do not convince me. What changes are they claiming? Is it a shift? A loss of a second band?

Subsection "*Drosophila* provides a sensitive system for investigating the effect of mutations on PCP": I do not think it\'s appropriate to speculate these shifts may reflect phosphorylation here. Either do the simple experiment or move this to the Discussion section.

3\) Overall lack of clarity: The experiments here are good ones, and overall, I find them compelling. Just the same, they are complex and must be explained clearly. Confusing and even misleading statements include:

Subsection "Dominant behavior and protein localization defects in the majority of mutations": \"....comparison of localization of \"endogenous wt-Vang....\"\" The interior set of quotation marks here are the authors, indicating that even they know this experiment has nothing to do with actual endogenous vangl. The word endogenous must be removed and the authors must make it clear that this experiment looks at the effect of over-expressed mutant vangl on co-overexpressed mutant vangl.

Subsection "Dominant behavior and protein localization defects in the majority of mutations": \"...suggestive of competition from the over-expressed Vang-flag for membrane recruitment. I concur with the authors\' interpretation, but this result contradicts their claim that their overexpressions \"remain within physiological levels\". This should be stated and addressed.

Subsection "Mutants show altered membrane localization in rescue conditions": \"as compared to wt-Vang.\" Unless I am mistaken, this should be corrected to indicate that it is as compared to OVEREXPRESSED wt-Vang.

4\) Subsection "Mutations associated with reduced membrane localization or loss in protein function disrupt effector binding". An alternative interpretation is that these mutations lead to trapping of Vang in the ER or Golgi, where it cannot access cytoplasmic proteins such as Dvl, thus leading to the observed loss of binding. This is known to be the case for D317E, so this possibility should be raised here.

5\) I think it would be great to include a table that summarizes the data for each mutation and ALSO summarizes the associated human phenotype (i.e. the specifics of the NTD for each).

Reviewer \#2:

Humphries et al., report the most comprehensive to date in vivo study in the *Drosophila* model of neural tube defect (NTD) associate mutations in VANGL2 and VANGL1, the core (and as the authors argue the most \"specific) component of the Planar Cell Polarity pathway. A subset of six missense mutations associated with NTDs in human and mouse in the C-terminal region of VANGL is studied. The authors leverage the advantage of the *Drosophila* model, in which the PCP pathway has been discovered and is arguably best understood. Using Gal4/UAS overexpression system they express the *Drosophila* Flagx3-tagged Vangl protein with the NTD mutations in the equivalent amino acid residues in wild type (overexpression) and vangl2 mutant background (rescue) and quantifying the wing hair orientation, as well as intracellular/tissue distribution of the (tagged) mutant and endogenous Vangl2 proteins, they conclude that the investigated candidate mutations are causative, and some work as antimorphs, hypermorphs, and one as a hypomorph. They identify reduced membrane localization, reduced interaction with intracellular effectors such ad Dsh, Pk, and Scribble and the interference with the membrane localization of the endogenous Vang as key molecular defects of the mutant proteins. One interesting insight is that \"these mutations do not show specificity for a particular effector but instead a general reduction in binding\" what the authors interpret as an effect of the mutations on \"the integrity of the entire protein\".

Whereas, some studies of VANGL mutations have been reported in other systems (zebrafish, mammalian cell culture), this is the most comprehensive in vivo study. The manuscript reports a large amount of data, is well-reasoned and clearly presented. The authors carefully assess also the level of the analyzed proteins, their mobility in gel electrophoresis, and intracellular distribution. In combination with functional studies this allows them to deduce how individual mutations affect function of the various mutant proteins in PCP signaling in vivo. This confirms and significantly extends some of the previous work (e.g. on the hypomorphic nature of the Vangl2Lp424 -R259L mutation). As such the study should be of interest to the scientific community. However, there are several questions about the interpretations and limitations of the experimental approach that need to be addressed before the manuscript is suitable for publication.

The study is a missed opportunity, because the current experimental approach has limitations as discussed below. Indeed, it is somewhat surprising that in times when genome editing in *Drosophila* is feasible, the author chose ectopic overexpression rather than engineering these mutations into the endogenous locus.

The limitation of the current overexpression approach is best seen in the rescue experiments. Here, the authors used actin-Gal4 driven expression, which as the authors state \"due to the higher than endogenous expression levels of the transgenes, we observed a gain-of-function phenotype with wt-Vang (Figure 4A). Despite this effect, we were able to observe hair reorientation patterns in the absence of endogenous Vang that were consistent with the experiments described above\". As planar cell polarity and processes regulated by it are exquisitely sensitive to the level of Vangl expression (and other PCP proteins), it has been difficult to rescue Vang/Vangl mutant phenotypes by ectopic expression in any system. This also confounds the interpretation of the results of these experiments.

In the rescue experiments in the eye, e.g. Figure 5 it appears that even the proposed dominant negative mutant forms provide some rescuing activity. Could the authors comment on this?

On the other hand, the rescue experiments in the wing, do not allow sufficient resolution to ask whether the cell polarity phenotypes in the wing of vang-/- mutants overexpressing the proposed dominant negative Vang mutant proteins are identical to vang mutants, or stronger, or possibly different. This would allow to distinguish between the antimorphic activity of these proteins being exerted through their effect on endogenous Vang protein (as seen in overexpression experiments) or possibly on other proteins as well.

Reviewer \#3:

In this manuscript, Humphries et al. use *Drosophila* to examine several mammalian Vangl1/2 mutations that have been associated with neural tube defects. Equivalent mutations were made in *Drosophila* Vang in overexpression systems, with all versions FLAG tagged and placed into attP/B sites for equivalent transcript expression. D317E, R321L, R332H, V391T, K418C and K577H mutations were examined. Overexpression of wt-Vang leads to consistent patterns of hair reorientation in the wing, and the authors found that overexpression of different Vangl mutations generally yields different patterns. They also found that a subset of the mutations have different protein mobility, consistent with the possibility that phosphorylation was altered, although phosphatase treatment was not used to confirm this. Staining revealed some of the mutations have altered localization while others had normal membrane localization. These data led the authors to conclude the D317E and K577H are dominant-negative alleles, and disrupt the localization of wildtype Vang, R332H and K418C are dominant mutations which remain at the membrane, R321L is a hypomorph and V391T is a mild GOF allele. The authors also expressed these alleles in the eye in Vangl mutants, using actin Gal4 and sep-Gal4. Binding to Dsh and Prickle was tested for all the alleles in S2 cells, and decreased interactions were noted for a subset of the alleles (317,321,577). The authors also used pull-down experiments to determine the Dgo binding to Vang requires Vang 303-322.

The experiments are well described, the data are well presented, and a significant amount of work was put into generating and analyzing all of the alleles. This study supports the proposal that the human-derived mutations cause PCP defects. Largely the work also supports previous studies in mouse models, and studies in other systems (MDCK cells and zebrafish) of Vangl alleles, although certain alleles act differently in the *Drosophila* system.

However, while this study supports the proposal that *Drosophila* can be used to model human mutations to probe for causality, the paper does not lead to significant new insights into how planar cell polarity is established, nor why these mutations lead to NTD. Ideally these mutations would be made in the endogenous locus, using CRISPR, and the presence of wildtype Vang complicates the interpretation in the wing. In addition, the high levels of expression precluded the authors examining PCP localization of their alleles. Overall, this paper seems more suited to a journal such as Genetics.

10.7554/eLife.53532.sa2

Author response

> We are enclosing the unedited version of the three reviewers comments, as they had some disagreements between them to which we wanted you to be privy. However, after discussion, the reviewers agreed that your paper is suitable for publication in eLife but that it will require extensive editing to make it more reader friendly for a broad audience (rather than just Drosophilists), and that it is better polished. Note that in the future, a more sophisticated approach should be envisaged using CRISPR technology and that point mutations in the endogenous gene will become the norm, rather than overexpression studies.
>
> Reviewer \#1:
>
> I quite like this new paper, which attacks the knotty problem of assessing pathogenicity within the rapidly expanding universe of disease associated variants from human patients. NTDs are an important problem, and the PCP genes are well known to be associated with NTDs. However, for the vast majority of variants we have little information relating genotype to phenotype. Here, the authors exploit the unique advantages of the *Drosophila* system to assess the pathogenicity of several variants in Vangl. The paper is very important, then, for developing a new system in which such pathogenicity can be assessed in the biologically relevant setting of a planar polarized epithelium. It therefore lays down the groundwork for systematic assessment of PCP variants in human disease.

We thank the reviewer for their kind comments and are glad they liked our study.

> That said, the paper suffers from being inaccessible to non-Drosopholists and for providing too little context for the findings. With more effort put into the writing, this paper would be an excellent fit for eLife.

Our apologies, we have worked to address this and are grateful to the reviewer for pointing out the areas of greatest concern. We have also used a FijiWingsPolarity software based presentation to replace the schematic drawings of wings within Figure 3 and Figure 4. This is in order to promote consistency with our analysis in Figure 2 and also to allow readers an easier interpretation of the different phenotypic features and patterns. We have moved the schematic drawings to the supplement, so we have two ways of representing the data, again hopefully improving accessibility for a wider audience.

> Essential revisions:
>
> 1\) Improved scholarship would help: The significance of this paper rests in the synthesis of ideas and the integration of scientific communities (i.e. It exploits model system (fly) genetics to understand human disease genetics). To be effective, then, the paper must not alienate any of the stakeholders. So, the biggest liability is the paper\'s failure to meaningfully deal with the literature outside of the fly. This must be corrected:
>
> Introduction. It\'s not clear why the Kibar 2007 paper is cited here. It is not a review of NTDs, but rather a primary paper showing for the first time the Vangl2 is mutated in human NTDs. It would more properly be cited in passages linking Vangl2 to NTDs (i.e. later in the Introduction).

Thank you for pointing this out, we have removed the citation. As we have cited a comprehensive review regarding the link between Vangl and human NTD in the introduction we have chosen to cite the Kibar, 2007 when directly referring to the findings of the paper e.g. Introduction, subsection "Mutations associated with mammalian NTD can be found throughout the C-terminal tail of *Vangl* genes".

> Introduction. Several errors: Tada and Smith, 2000 did not look at neutral tube closure or neural tissue at all. It should be removed. Wallingford et al., 2002 is a review of PCP and convergent extension and does not mention neural tube closure in any depth; this should be replaced with the relevant paper for the link to neural plate width, which is Wallingford and Harland, 2002. Likewise, while the Wang, 2006b reference does describe PCP genes and neural tube closure, Wang, 2006a is the paper that actually links PCP to neural plate width. It should be cited here.

Our apologies we made a mistake and referenced the wrong Wallingford and Wang papers, thank you for alerting us to this. We have corrected this error.

> Introduction: Wang, 2006b should be included in the list here.

We have added this reference, apologies for the initial omission.

> Introduction: The Looptail mouse was studied by geneticists for decades before it was identified as a mutation in Vangl2. That work is notable because the odd penetrance of the allele led to the conclusion that the mutation was \"semi-dominant,\" a decades-old conclusion confirmed by the nice experiments here. I recommend the authors discuss and cite (at a minimum) the following:
>
> Developmental basis of severe neural tube defects in the loop-tail (Lp) mutant mouse: use of microsatellite DNA markers to identify embryonic genotype.
>
> Copp, Checiu and Henson, 1994.
>
> All-or-none craniorachischisis in Loop-tail mutant mouse chimeras.
>
> Musci and Mullen, 1990.
>
> Strong and Hollander, (1949).
>
> These papers might also be re-introduced in the Discussion section.
>
> Thank you for pointing this out. We have included these references and added more discussion surrounding the original *Lp* mouse work, e.g. lines Introduction and subsection "Functional definition of both dominant negative and gain-of-function mutations".
>
> The Introduction almost seems to be specifically designed to irritate non-Drosophilists. One might read a passage like this and retort that the linkage of PCP to NTDs is really the only truly important PCP finding, and it was made in the mouse. Why risk it?

This sentence has been removed to reflect the reviewer's concerns. Our intention was only to highlight the advantages of using the *Drosophila* system for certain types of analysis due to its simplicity compared to mammalian systems, which we discuss later in the text.

> 2): Not written accessibly: I was able eventually to figure out what was what in Figure 2, but this critical figure was very poorly described.
>
> Subsection "*Drosophila* provides a sensitive system for investigating the effect of mutations on PCP", I don\'t know know what \"attP/B sites\" are, would nice to have this system explained.

Apologies for not having explained this clearly. We have added text to better explain the attP/B system that allows direct comparison of individual transgenes as they're all expressed from the same genomic insertion. Please see subsection "*Drosophila* provides a sensitive system for investigating the effect of mutations on PCP".

> Figure 2. I do not know what w1118 is. After some digging, I find it is the control. But then, why is it shown after the mutant? What are we meant to compare the others to? The mutant or the control?

The *w1118* genotype is used as a reference control where no phenotype is observed ("wild-type"). We have reordered the figure to have this "wild-type" reference control first. We describe now in the main text that *w1118* is genetically wild-type, and we have now added more text to hopefully make clearer to a wider audience what this fly genotype is and why we include it. Please see subsection "*Drosophila* provides a sensitive system for investigating the effect of mutations on PCP" and Figure 2 legend.

The different phenotypes can and should be compared to the reference control, the loss-of-function, and the wt overexpression. This is most useful, as the different mammalian mutants show different hair-reorientation patterns that are reminiscent of the three aforementioned genotypes. These different patterns and phenotypes are discussed within the text, e.g. subsection "*Drosophila* provides a sensitive system for investigating the effect of mutations on PCP". For statistical analysis we compared the wt overexpression to each mutant overexpression, as we feel this is the most appropriate comparison and control.

> Figure 2. \"ac\>\" is never explicitly defined, though I gather it means the actin-Gal4 driven construct.

Thank you for pointing this out. It is has now been introduced both in the main text and in the figure legend. subsection "*Drosophila* provides a sensitive system for investigating the effect of mutations on PCP" and Figure 2 legend.

> Figure 2. All the text in B is unreadably small.
>
> We apologize for this mishap, we have increased the text size in the figure.
>
> Subsection "*Drosophila* provides a sensitive system for investigating the effect of mutations on PCP": The text says \"all showed a notable change in protein mobility, but the data in Figure 2C do not convince me. What changes are they claiming? Is it a shift? A loss of a second band?
>
> There are a number of papers detailing the phosphorylation of Vang(l) proteins and associated changes in protein mobility as referenced in the manuscript. This includes our labs previous study (Kelly et al., 2016) as well as other *Drosophila* work (Strutt et al., 2019). Please note the variation in appearance of the phospho band shifts here. We find that loss in phosphorylation can lead to a single lower band or collapsed bands depending on the gel. To further clarify this point, we have repeated these experiments to show the change in protein mobility more consistently throughout the manuscript and the new data can be seen in Figure 2---figure supplement 1C.
>
> Subsection "*Drosophila* provides a sensitive system for investigating the effect of mutations on PCP": I do not think it\'s appropriate to speculate these shifts may reflect phosphorylation here. Either do the simple experiment or move this to the Discussion section.

We have performed the respective experiments with phosphatase (PPase) treatment, the new data set directly comparing controls and PPase treated samples can be seen in the new Figure 2---figure supplement 1C.

> 3\) Overall lack of clarity: The experiments here are good ones, and overall, I find them compelling. Just the same, they are complex and must be explained clearly. Confusing and even misleading statements include:
>
> Subsection "Dominant behavior and protein localization defects in the majority of mutations": \"....comparison of localization of \"endogenous wt-Vang....\"\" The interior set of quotation marks here are the authors, indicating that even they know this experiment has nothing to do with actual endogenous vangl. The word endogenous must be removed and the authors must make it clear that this experiment looks at the effect of over-expressed mutant vangl on co-overexpressed mutant vangl.

We apologize for the misleading comment, it was not our intention. We have added to the text to make the experimental approach easier to understand. Please see subsection "Dominant behavior and protein localization defects in the majority of mutations" in the revised manuscript.

> Subsection "Dominant behavior and protein localization defects in the majority of mutations": \"...suggestive of competition from the over-expressed Vang-flag for membrane recruitment. I concur with the authors\' interpretation, but this result contradicts their claim that their overexpressions \"remain within physiological levels\". This should be stated and addressed.

We appreciate the comment and concern of the reviewer, however, we disagree that there is a contradiction. In this case the Vang-flag is overexpressed, while Vang-GFP remains within physiological levels, as shown by the absence of any GOF phenotypic change by the Vang-GFP expression (Figure 3---figure supplement 1A). The change in Vang-GFP localization is due to the abundance of Vang-flag within the cell. We believe that better introduction of the experiment has made clearer the difference in expression levels between the Vang-flag mutants and Vang-GFP.

> Subsection "Mutants show altered membrane localization in rescue conditions": \"as compared to wt-Vang.\" Unless I am mistaken, this should be corrected to indicate that it is as compared to OVEREXPRESSED wt-Vang.

Thank you for pointing this out. Yes, this has been corrected.

> 4\) Subsection "Mutations associated with reduced membrane localization or loss in protein function disrupt effector binding". An alternative interpretation is that these mutations lead to trapping of Vang in the ER or Golgi, where it cannot access cytoplasmic proteins such as Dvl, thus leading to the observed loss of binding. This is known to be the case for D317E, so this possibility should be raised here.

We have discussed this interpretation in the Discussion section. We feel the data from the *Lp* mouse more likely reflect a loss of binding due to altered structure rather than trapping away from effectors. This is due to the observation that Sec24b is unable to bind and this is the reason for its localization in the ER (discussed in subsection "Functional definition of both dominant negative and gain-of-function mutations"). We also think that there is not strong enough evidence to show that the D317E and K577H mutants are trapped within a particular sub compartment, so we are reluctant to state this within the text. We do however discuss the trapping of *Lp* in the ER, so that readers are aware of these findings (subsection "*Drosophila* as model to define causative nature of human mutations"). Finally, we know that R321L can be membrane localized and so this mutant would be able to access cytoplasmic proteins and it still shows a binding defect.

> 5\) I think it would be great to include a table that summarizes the data for each mutation and ALSO summarizes the associated human phenotype (i.e. the specifics of the NTD for each).
>
> Thank you for the suggestion. We agree that it would be nice to correlate the human data directly with our work. Unfortunately, we feel that this is not possible. As NTDs are very complex, it is clear that a number of factors combine to contribute to the overall phenotype (as discussed in our manuscript, Introduction). We therefore feel that stating the phenotype of one particular patient would be an oversimplification, as we cannot be sure whether and what other factors are contributing to disease progression, this is also relevant when considering that some mutations are familial and family members show different phenotypic outcome. We have thus chosen to keep our summary table as in the original version, however, should the editors feel differently on this point, it would of course be possible to adjust this and add this information.
>
> Reviewer \#2:
>
> Humphries et al., report the most comprehensive to date in vivo study in the Drosophila model of neural tube defect (NTD) associate mutations in VANGL2 and VANGL1, the core (and as the authors argue the most \"specific) component of the Planar Cell Polarity pathway. A subset of six missense mutations associated with NTDs in human and mouse in the C-terminal region of VANGL is studied. The authors leverage the advantage of the *Drosophila* model, in which the PCP pathway has been discovered and is arguably best understood. Using Gal4/UAS overexpression system they express the *Drosophila* Flagx3-tagged Vangl protein with the NTD mutations in the equivalent amino acid residues in wild type (overexpression) and vangl2 mutant background (rescue) and quantifying the wing hair orientation, as well as intracellular/tissue distribution of the (tagged) mutant and endogenous Vangl2 proteins, they conclude that the investigated candidate mutations are causative, and some work as antimorphs, hypermorphs, and one as a hypomorph. They identify reduced membrane localization, reduced interaction with intracellular effectors such ad Dsh, Pk, and Scribble and the interference with the membrane localization of the endogenous Vang as key molecular defects of the mutant proteins. One interesting insight is that \"these mutations do not show specificity for a particular effector but instead a general reduction in binding\" what the authors interpret as an effect of the mutations on \"the integrity of the entire protein\".
>
> Whereas, some studies of VANGL mutations have been reported in other systems (zebrafish, mammalian cell culture), this is the most comprehensive in vivo study. The manuscript reports a large amount of data, is well-reasoned and clearly presented. The authors carefully assess also the level of the analyzed proteins, their mobility in gel electrophoresis, and intracellular distribution. In combination with functional studies this allows them to deduce how individual mutations affect function of the various mutant proteins in PCP signaling in vivo. This confirms and significantly extends some of the previous work (e.g. on the hypomorphic nature of the Vangl2Lp424 -R259L mutation). As such the study should be of interest to the scientific community. However, there are several questions about the interpretations and limitations of the experimental approach that need to be addressed before the manuscript is suitable for publication.
>
> We thank the reviewer for their positive comments surrounding the findings of our study.
>
> The study is a missed opportunity, because the current experimental approach has limitations as discussed below. Indeed, it is somewhat surprising that in times when genome editing in Drosophila is feasible, the author chose ectopic overexpression rather than engineering these mutations into the endogenous locus.

We appreciate that these experiments would of have been an excellent addition, however, we chose the UAS/Gal4 attP/B system to be able to manipulate levels and dynamics of expression to answer different questions. We have discussed our reasoning for our approach in the cover letter, and for completeness we include our comments again here:

We were particularly interested to explore the nature of the mutations, e.g. gain of function or loss of function. Therefore, we felt the overexpression experiment would nicely address this, shown by either an enhancement, reduction or no change in phenotype as compared to wt overexpression. This coupled with the rescue experiment could then delineate between hypermorphic, hypomorphic, null or dominant negative mutations. As the Vang heterozygote displays very little phenotype, we were concerned that introduction of the mutation in the endogenous locus would not yield as clear results, especially for weaker mutations. This is also complicated by the fact that loss-of-function and gain-of-function mutations in core PCP genes both lead to non-polar, abnormal localization. The mutations appear in heterozygote in human patients, however, in these cases the background must be favorable to see pathogenesis (family members with the mutation do not always show disease progression). While we feel we address what we set out to study, showing that mutations found in the human patients do show PCP defects, the next step of course would be to study the intricacies of PCP signaling in an endogenous setting.

> The limitation of the current overexpression approach is best seen in the rescue experiments. Here, the authors used actin-Gal4 driven expression, which as the authors state \"due to the higher than endogenous expression levels of the transgenes, we observed a gain-of-function phenotype with wt-Vang (Figure 4A). Despite this effect, we were able to observe hair reorientation patterns in the absence of endogenous Vang that were consistent with the experiments described above\". As planar cell polarity and processes regulated by it are exquisitely sensitive to the level of Vangl expression (and other PCP proteins), it has been difficult to rescue Vang/Vangl mutant phenotypes by ectopic expression in any system. This also confounds the interpretation of the results of these experiments.
>
> In the rescue experiments in the eye, e.g. Figure 5 it appears that even the proposed dominant negative mutant forms provide some rescuing activity. Could the authors comment on this?

We of course agree that there is a limitation to this approach, however we included the rescue experiments to support our findings from the dominant assays (overexpression -- phenotype and localization). We also feel that they allowed for further interpretation. For example, without these experiments we would have not been able to confirm that R321L is a hypomorph and not a null allele. While the rescue is not perfect, as we acknowledge within the text, we think that the data is fully consistent with our other results. In regards to the dominant negative rescue, we indeed believe that some function of Vang is retained in these mutants that enables the very minor rescue that we see. We have now discussed this in the manuscript to clarify these points (subsection "Rescue experiments in the eye confirm loss-of-function and gain-of-function behavior).

> On the other hand, the rescue experiments in the wing, do not allow sufficient resolution to ask whether the cell polarity phenotypes in the wing of vang-/- mutants overexpressing the proposed dominant negative Vang mutant proteins are identical to vang mutants, or stronger, or possibly different. This would allow to distinguish between the antimorphic activity of these proteins being exerted through their effect on endogenous Vang protein (as seen in overexpression experiments) or possibly on other proteins as well.

We appreciate that the reviewer raises an interesting point. We fully agree and would be keen to follow up the D317E and K577H mutants in a future study, to see whether their dominance impacts only Vang or indeed other PCP effectors. These findings could also have interesting implications for the *Lp* mouse.

> Reviewer \#3:
>
> In this manuscript, Humphries et al. use *Drosophila* to examine several mammalian Vangl1/2 mutations that have been associated with neural tube defects. Equivalent mutations were made in *Drosophila* Vang in overexpression systems, with all versions FLAG tagged and placed into attP/B sites for equivalent transcript expression. D317E, R321L, R332H, V391T, K418C and K577H mutations were examined. Overexpression of wt-Vang leads to consistent patterns of hair reorientation in the wing, and the authors found that overexpression of different Vangl mutations generally yields different patterns. They also found that a subset of the mutations have different protein mobility, consistent with the possibility that phosphorylation was altered, although phosphatase treatment was not used to confirm this. Staining revealed some of the mutations have altered localization while others had normal membrane localization. These data led the authors to conclude the D317E and K577H are dominant-negative alleles, and disrupt the localization of wildtype Vang, R332H and K418C are dominant mutations which remain at the membrane, R321L is a hypomorph and V391T is a mild GOF allele. The authors also expressed these alleles in the eye in Vangl mutants, using actin Gal4 and sep-Gal4. Binding to Dsh and Prickle was tested for all the alleles in S2 cells, and decreased interactions were noted for a subset of the alleles (317,321,577). The authors also used pull-down experiments to determine the Dgo binding to Vang requires Vang 303-322.
>
> The experiments are well described, the data are well presented, and a significant amount of work was put into generating and analyzing all of the alleles. This study supports the proposal that the human-derived mutations cause PCP defects. Largely the work also supports previous studies in mouse models, and studies in other systems (MDCK cells and zebrafish) of Vangl alleles, although certain alleles act differently in the *Drosophila* system.
>
> We thank the reviewer for appreciating the effort we have taken with our study, and are glad they found the manuscript and study to be well executed.
>
> However, while this study supports the proposal that *Drosophila* can be used to model human mutations to probe for causality, the paper does not lead to significant new insights into how planar cell polarity is established, nor why these mutations lead to NTD. Ideally these mutations would be made in the endogenous locus, using CRISPR, and the presence of wildtype Vang complicates the interpretation in the wing. In addition, the high levels of expression precluded the authors examining PCP localization of their alleles. Overall, this paper seems more suited to a journal such as Genetics.

We very much appreciate the comment of the reviewer and we have commented on the reason for our approach in the cover letter and above (please see also below), and of course we agree that next steps would be to introduce the mutations into the endogenous locus. This would then allow for further analysis of how PCP signaling itself is altered in the mutants and insight into PCP establishment mechanisms. However, this was not the goal of our study, in fact we feel that our work here now validates the utility of such an approach (subsection "*Drosophila* as model to define causative nature of human mutations").

In response to "using CRIPR to introduce the mutations in the endogenous locus":

We were particularly interested to explore the nature of the mutations, e.g. gain of function or loss of function. Therefore, we felt the overexpression experiment would nicely address this, shown by either an enhancement, reduction or no change in phenotype as compared to wt overexpression. This coupled with the rescue experiment could then delineate between hypermorphic, hypomorphic, null or dominant negative mutations. As the Vang heterozygote displays very little phenotype, we were concerned that introduction of the mutation in the endogenous locus would not yield as clear results, especially for weaker mutations. This is also complicated by the fact that loss-of-function and gain-of-function mutations in core PCP genes both lead to non-polar, abnormal localization. The mutations appear in heterozygote in human patients, however, in these cases the background must be favorable to see pathogenesis (family members with the mutation do not always show disease progression). While we feel we address what we set out to study, showing that mutations found in the human patients do show PCP defects, the next step of course would be to study the intricacies of PCP signaling in an endogenous setting.

In the case of the majority of these mutants, there was no evidence to suggest that they could impact Vang function. Therefore, we feel that our study importantly shows this, and thus defects in PCP signaling can be causative for NTD in patients, which we feel is a significant addition to the field.
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